1
|
Siano MA, Marchetti V, Pagano S, Di Candia F, Alessio M, De Brasi D, De Luca A, Pinna V, Sestito S, Concolino D, Tartaglia M, Strisciuglio P, D'Esposito V, Cabaro S, Perruolo G, Formisano P, Melis D. Risk of autoimmune diseases in patients with RASopathies: systematic study of humoral and cellular immunity. Orphanet J Rare Dis 2021; 16:410. [PMID: 34600590 PMCID: PMC8487584 DOI: 10.1186/s13023-021-02050-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Accepted: 09/19/2021] [Indexed: 01/21/2023] Open
Abstract
BACKGROUND Abnormalities of the immune system are rarely reported in patients affected by RASopathies. Aim of the current study was to investigate the prevalence of immune system dysfunction in a cohort of patients affected by RASopathies. STUDY DESIGN A group of 69 patients was enrolled: 60 at the Federico II University, Naples, 7 at University Magna Graecia of Catanzaro, 2 at "Scuola Medica Salernitana", Salerno. An age- and sex-matched control group was also enrolled. Autoimmune disorders were investigated according to international consensus criteria. Immune framework was also evaluated by immunoglobulin levels, CD3, CD4, CD8, CD19, CD56 lymphocyte subpopulations, autoantibodies levels and panel of inflammatory molecules, in both patients and controls. RESULTS Frequent upper respiratory tract infections were recorded in 2 patients; pneumonia, psoriasis and alopecia in single patients. Low IgA levels were detected in 8/44 patients (18.18%), low CD8 T cells in 13/35 patients (37.14%). Anti-tg and anti-TPO antibodies were detected in 3/24 patients (12.5%), anti r-TSH in 2 cases (8.33%), all in euthyroidism. Serum IgA and CD8 levels were significantly lower in patients than in controls (p 0.00685; p 0.000656 respectively). All tested patients showed increased inflammatory molecules compared to controls. These findings may anticipate the detection of overt autoimmune disease. CONCLUSIONS Patients affected by RASopathies are at risk to develop autoimmune disorders. Routine screening for autoimmunity is recommended in patients with RASopathy.
Collapse
Affiliation(s)
- M A Siano
- Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", Salerno, Italy
| | - V Marchetti
- Dipartimento di Scienze Mediche Traslazionali- Sez. di Pediatria, Università degli Studi di Napoli "Federico II", Napoli, Italy
| | - S Pagano
- Dipartimento di Scienze Mediche Traslazionali- Sez. di Pediatria, Università degli Studi di Napoli "Federico II", Napoli, Italy
| | - F Di Candia
- Dipartimento di Scienze Mediche Traslazionali- Sez. di Pediatria, Università degli Studi di Napoli "Federico II", Napoli, Italy
| | - M Alessio
- Dipartimento di Scienze Mediche Traslazionali- Sez. di Pediatria, Università degli Studi di Napoli "Federico II", Napoli, Italy
| | - D De Brasi
- Dipartimento di Pediatria, A.O.R.N. "Santobono-Pausillipon", Napoli, Italy
| | - A De Luca
- Molecular Genetics Unit, Fondazione Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Foggia, Italy
| | - V Pinna
- Molecular Genetics Unit, Fondazione Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Foggia, Italy
| | - S Sestito
- Dipartimento di Medicina Clinica e Sperimentale, Università "Magna Graecia" di Catanzaro, Catanzaro, Italy
| | - D Concolino
- Dipartimento di Medicina Clinica e Sperimentale, Università "Magna Graecia" di Catanzaro, Catanzaro, Italy
| | - M Tartaglia
- Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, Rome, Italy
| | - P Strisciuglio
- Dipartimento di Scienze Mediche Traslazionali- Sez. di Pediatria, Università degli Studi di Napoli "Federico II", Napoli, Italy
| | - V D'Esposito
- Dipartimento di Scienze Mediche Traslazionali, Università degli Studi di Napoli "Federico II" & Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale Delle Ricerche, Napoli, Italy
| | - S Cabaro
- Dipartimento di Scienze Mediche Traslazionali, Università degli Studi di Napoli "Federico II" & Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale Delle Ricerche, Napoli, Italy
| | - G Perruolo
- Dipartimento di Scienze Mediche Traslazionali, Università degli Studi di Napoli "Federico II" & Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale Delle Ricerche, Napoli, Italy
| | - P Formisano
- Dipartimento di Scienze Mediche Traslazionali, Università degli Studi di Napoli "Federico II" & Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale Delle Ricerche, Napoli, Italy
| | - D Melis
- Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", Salerno, Italy.
- Dipartimento di Scienze Mediche Traslazionali- Sez. di Pediatria, Università degli Studi di Napoli "Federico II", Napoli, Italy.
| |
Collapse
|
2
|
Conti A, Burastero GJ, Hales BJ, Breda D, Alessio M, Burastero SE. IgE reactivity to house dust mite allergen components in sensitized asymptomatic subjects: a role for Der p 20. J BIOL REG HOMEOS AG 2021; 35:669-676. [PMID: 33851528 DOI: 10.23812/21-07-l] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A Conti
- Proteome Biochemistry, IRCCS - San Raffaele Scientific Institute, Milan, Italy
| | - G J Burastero
- Proteome Biochemistry, IRCCS - San Raffaele Scientific Institute, Milan, Italy
| | - B J Hales
- Telethon Kids Institute, Center for Child Health Research, University of Western Australia, Perth, Australia
| | - D Breda
- Proteome Biochemistry, IRCCS - San Raffaele Scientific Institute, Milan, Italy
| | - M Alessio
- Proteome Biochemistry, IRCCS - San Raffaele Scientific Institute, Milan, Italy
| | - S E Burastero
- Cellular and Molecular Allergology Unit, IRCCS - San Raffaele Hospital, Milan Italy
| |
Collapse
|
3
|
Geraldo AF, Caorsi R, Tortora D, Gandolfo C, Ammendola R, Alessio M, Conti G, Insalaco A, Pastore S, Martino S, Ceccherini I, Signa S, Gattorno M, Rossi A, Severino M. Widening the Neuroimaging Features of Adenosine Deaminase 2 Deficiency. AJNR Am J Neuroradiol 2021; 42:975-979. [PMID: 33632736 DOI: 10.3174/ajnr.a7019] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2020] [Accepted: 11/23/2020] [Indexed: 02/06/2023]
Abstract
Adenosine deaminase 2 deficiency (OMIM #615688) is an autosomal recessive disorder characterized by a wide clinical spectrum, including small- and medium-sized vessel vasculopathies, but data focusing on the associated neuroimaging features are still scarce in the literature. Here, we describe the clinical neuroimaging features of 12 patients with genetically proven adenosine deaminase 2 deficiency (6 males; median age at disease onset, 1.3 years; median age at genetic diagnosis, 15.5 years). Our findings expand the neuroimaging phenotype of this condition demonstrating, in addition to multiple, recurrent brain lacunar ischemic and/or hemorrhagic strokes, spinal infarcts, and intracranial aneurysms, also cerebral microbleeds and a peculiar, likely inflammatory, perivascular tissue in the basal and peripontine cisterns. Together with early clinical onset, positive family history, inflammatory flares and systemic abnormalities, these findings should raise the suspicion of adenosine deaminase 2 deficiency, thus prompting genetic evaluation and institution of tumor necrosis factor inhibitors, with a potential great impact on neurologic outcome.
Collapse
Affiliation(s)
- A F Geraldo
- Neuroradiology Unit (A.F.G., D.T., R.A., A.R., M.S.), IRCCS Istituto Giannina Gaslini, Genoa, Italy.,Diagnostic Neuroradiology Unit, Imaging Department (A.F.G.), Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
| | - R Caorsi
- Center for Autoinflammatory Diseases and Immunodeficiencies (R.C., S.S., M.G.), IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - D Tortora
- Neuroradiology Unit (A.F.G., D.T., R.A., A.R., M.S.), IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - C Gandolfo
- Interventional Unit (C.G.), IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - R Ammendola
- Neuroradiology Unit (A.F.G., D.T., R.A., A.R., M.S.), IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - M Alessio
- Department of Translational Medical Sciences (M.A.), Federico II University of Naples, Naples, Italy
| | - G Conti
- Pediatric Nephrology and Rheumatology Unit (G.C.), AOU G Martino, Messina, Italy
| | - A Insalaco
- Division of Rheumatology (A.I.), IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
| | - S Pastore
- Department of Pediatrics (S.P.), Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy
| | - S Martino
- Division of Pediatric Immunology and Rheumatology, Department of Public Health and Pediatrics (S.M.), Regina Margherita Children Hospital, University of Turin, Turin, Italy
| | - I Ceccherini
- UOSD Genetics and Genomics of Rare Diseases (I.C.), IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - S Signa
- Center for Autoinflammatory Diseases and Immunodeficiencies (R.C., S.S., M.G.), IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - M Gattorno
- Center for Autoinflammatory Diseases and Immunodeficiencies (R.C., S.S., M.G.), IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - A Rossi
- Neuroradiology Unit (A.F.G., D.T., R.A., A.R., M.S.), IRCCS Istituto Giannina Gaslini, Genoa, Italy.,Department of Health Sciences (DISSAL) (A.R.), University of Genoa, Genoa, Italy
| | - M Severino
- Neuroradiology Unit (A.F.G., D.T., R.A., A.R., M.S.), IRCCS Istituto Giannina Gaslini, Genoa, Italy
| |
Collapse
|
4
|
Gallizzi R, Bustaffa M, Mazza F, Sutera D, Fabio G, Obici L, Alessio M, Rigante D, Cantarini L, Insalaco A, Cattalini M, Maggio MC, Simonini G, Olivieri AN, Pastore S, Lancieri M, Ruperto N, Gattorno M. OP0273 ADHERENCE TO COLCHICINE TREATMENT AND COLCHICINE RESISTANCE IN A MULTICENTRIC FMF NATIONAL COHORT. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1402] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Colchicine is the standard treatment for Familiar Mediterranean Fever (FMF), however about 5% of patients experience colchicine resistance. There is no standard definition of colchicine resistance. Recently a panel of experts elaborated a new definition based on a Delphi consensus approach.Objectives:We aim to describe main features of the disease and clinical outcome of a cohort of FMF patients with particular interest on the colchicine resistance and tolerability according to the definitions proposed by the recent consensus.Methods:Since November 2009, 425 Italian pediatric and adult FMF patients (pts) from 13 centers were enrolled in a national longitudinal cohort study, using the international EUROFEVER registry. Demographic, genetic and clinical data, including response to treatment, were analyzed. Supplementary information on health related quality of life and treatment adherence was also collected by a specific questionnaire.Results:Complete information were available in 341 pts (189 M and 152 F, 211 children and 120 adults). The median age at disease onset was 5.0 years (1 m-59 y); the mean diagnostic delay was 8.7 y (range 0-61 y). The median age at enrollment was 12.1 y (range 3 m - 82 y). The MEFV genotype was the following: 103 (30.2%) pts carried biallelic pathogenic variants; 59 (17.3%) one pathogenic variants and one VOUS /LB variant; 27 (7.9%) had biallelic VOUS/LB variants; 97 (28.45%) were heterozygous for pathogenic variants; 30 (8.8%) were heterozygous for VOUS/LB, 25 (7.33%) were genetically negative.Colchicine treatment was used in 280 pts; during treatment, biologic treatment (anti-IL1) in 22 pts. 61 pts received NSAID or steroid on demand.We analyzed the behavior of the pts treated with colchicine according to the statements on colchicine resistance/intolerance defined by Ozen et al (1) (Table 1).Table 1.Adherence62% displayed a total adherence (> 90% of prescription); 10.8% a good adherence (50-89% of prescriptions); 1.9% poor adherence (< 50% of prescriptions); 0.9% no adherenceDose adjustment criteria/ Recommended maximum colchicine doseMean colchicine dose:Pts <5 years: 0.57mg/de (std. dev. 0.18)5-10 year: 0.77mg/die (std. dev. 0.23)10-18 years: 1.1mg/die (std. dev. 0.39)Adults: 1.16 mg/die (std. dev. 0.37)Pts with a dose inferior to the minimum recommended dose5-10 years: 2.5%10-18 years: 15%Adults: 4%Resistance to ColchicineResistance was be defined as persistence of fever attacks, despite optimal treatment. 41.6% pts had a complete disease control32.8% Pts had < 1 episode/month for 3 months25.5% had ≥1 episode/month for 3 monthsInclusion of secondary amyloidosis in the definition of colchicine resistance5 adult pts (1.5%) displayed amyloidosisColchicine intolerance11 pts (3.2%) withdraw colchicine because of drug intolerancePatient quality of life and patient-reported outcomes20.7% of pts experience fatigue or chronic pain, 16.9% limitations in daily activities, and 16.9% have lost school/work days.Conclusion:Almost 58% of FMF pts display disease activity despite colchicine treatment. The treatment is generally under-dosed, especially in children. The adherence and the compliance to the treatment is generally good.References:[1]Ozen S et all. Recommendation on colchicine dosing and definition of colchicine resistance/intolerance in the management of FMF. Pediatric Rheumatology, 2019.Acknowledgments:This research was financial supported by Novartis AGDisclosure of Interests:Romina Gallizzi: None declared, Marta Bustaffa: None declared, Francesca Mazza: None declared, Diana Sutera: None declared, Giovanna Fabio: None declared, Laura Obici: None declared, Maria Alessio: None declared, Donato Rigante: None declared, Luca Cantarini: None declared, Antonella Insalaco: None declared, Marco Cattalini: None declared, Maria Cristina Maggio: None declared, Gabriele Simonini: None declared, Alma Nunzia Olivieri: None declared, Serena Pastore: None declared, Maddalena Lancieri: None declared, Nicolino Ruperto Grant/research support from: Bristol-Myers Squibb, Eli Lily, F Hoffmann-La Roche, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sobi (paid to institution), Consultant of: Ablynx, AbbVie, AstraZeneca-Medimmune, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lily, EMD Serono, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, R-Pharma, Sanofi, Servier, Sinergie, Sobi, Takeda, Speakers bureau: Ablynx, AbbVie, AstraZeneca-Medimmune, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lily, EMD Serono, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, R-Pharma, Sanofi, Servier, Sinergie, Sobi, Takeda, Marco Gattorno Consultant of: Sobi, Novartis, Speakers bureau: Sobi, Novartis
Collapse
|
5
|
Genzano F, Funaro A, Alessio M, De Monte LB, Bellone G, Peruzzi L, Zaccolo M, Caligari-Cappino F, Malavasi F. Generation and Characterization of a Murine Monoclonal Antibody Specific for the Human T1-Cd5 Molecule. Int J Biol Markers 2018; 2:143-50. [PMID: 3330108 DOI: 10.1177/172460088700200302] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Murine monoclonal antibodies (MoAbs) have found widespread applications in the characterization of the molecular and functional features of lymphocyte differentiation antigens. The present paper summarizes the results of our work dealing with the production and selection of a murine MoAb recognizing a molecule expressed during the whole differentiative life of T lymphocytes. The MoAb CB01 resulted to be specific for an apparently unique epitope of the T-cell specific membrane glycoprotein T1-CD5.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/analysis
- Antibodies, Monoclonal/biosynthesis
- Antibody Specificity
- Antigen-Antibody Reactions
- Antigens, Differentiation, T-Lymphocyte/analysis
- Antigens, Differentiation, T-Lymphocyte/immunology
- Binding Sites, Antibody
- Binding, Competitive
- Electrophoresis, Polyacrylamide Gel
- Fluorescent Antibody Technique
- Humans
- Mice
- Mice, Inbred BALB C
- Precipitin Tests
- T-Lymphocytes/immunology
Collapse
Affiliation(s)
- F Genzano
- Dipartimento di Genetica, Biologia e Chimica Medica, Università di Torino, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Fusco V, Rossi M, De Martino I, Alessio M, Fasciolo A, Numico G. Incidence of osteonecrosis of the jaw (ONJ) in cancer patients with bone metastases treated with bisphosphonates and/or denosumab: some comments and questions. Acta Clin Belg 2018; 73:163-164. [PMID: 29111914 DOI: 10.1080/17843286.2017.1389473] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | - Maura Rossi
- Azienda Ospedaliera di Alessandria, Alessandria, Italy
| | | | | | | | | |
Collapse
|
7
|
Affiliation(s)
- A. Iovine
- Department of Ophthalmology, University of Napoli “Federico II”, Napoli - Italy
| | - F Fimiani
- Department of Ophthalmology, University of Napoli “Federico II”, Napoli - Italy
| | - P. Vassallo
- Department of Ophthalmology, University of Napoli “Federico II”, Napoli - Italy
| | - M. Alessio
- Department of Pediatrics, University of Napoli “Federico II”, Napoli - Italy
| | - A. Magli
- Department of Ophthalmology, University of Napoli “Federico II”, Napoli - Italy
| |
Collapse
|
8
|
Gambino A, Cabras M, Fusco V, Bertetto O, De Martino I, Alessio M, Numico G. Osteonecrosis of jaw (ONJ) after antiresorptive treatment (bisphosphonates, denosumab) of cancer-treatment induced bone loss (CTIBL): a negligible risk? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx436.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Migliario M, Mergoni G, Vescovi P, Martino ID, Alessio M, Benzi L, Renò F, Fusco V. Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition. Dent J (Basel) 2017; 5:dj5010013. [PMID: 29563419 PMCID: PMC5806981 DOI: 10.3390/dj5010013] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Revised: 03/03/2017] [Accepted: 03/10/2017] [Indexed: 11/16/2022] Open
Abstract
Osteonecrosis of the jaws (ONJ) in osteoporosis patients has been defined as rare, but the number of reported cases is increasing. We report a case of delayed ONJ diagnosis in a patient, who was being treated with alendronate, developing bone alterations both in maxilla and in mandible. Underestimation of ONJ incidence and missed or delayed ONJ diagnosis in osteoporosis patients might derive from lack of awareness of health providers as well as from an ONJ definition that is too restricted. The more recent definition of medication-related osteonecrosis of the jaws (MRONJ) released in 2014 by the American Association of Oral Maxillofacial Surgeons (AAOMS) accept fistula, besides bone exposure, as a major sign of disease, but it seems to be insufficient since it excludes all cases of ONJ disease without bone exposure. A new MRONJ definition is needed to avoid missing or delayed diagnosis.
Collapse
Affiliation(s)
- Mario Migliario
- Dental Clinic, Health Sciences Department, University of Eastern Piedmont "A. Avogadro", 28100, Novara, Italy.
| | - Giovanni Mergoni
- Oral Medicine and Laser Surgery Unit, University Center of Dentistry, Department of Medicine and Surgery, University of Parma, 43121, Parma, Italy.
| | - Paolo Vescovi
- Oral Medicine and Laser Surgery Unit, University Center of Dentistry, Department of Medicine and Surgery, University of Parma, 43121, Parma, Italy.
| | - Iolanda De Martino
- Centro di Documentazione Osteonecrosi dei Mascellari, 15121,Alessandria, Italy.
| | - Manuela Alessio
- Centro di Documentazione Osteonecrosi dei Mascellari, 15121,Alessandria, Italy.
| | - Luca Benzi
- Radiology Unit, Alessandria Hospital, 15121, Alessandria, Italy.
| | - Filippo Renò
- Innovative Research Laboratory for Wound Healing, Health Sciences Department, University of Eastern Piedmont "A. Avogadro", 28100, Novara, Italy.
| | - Vittorio Fusco
- Centro di Documentazione Osteonecrosi dei Mascellari, 15121,Alessandria, Italy.
- Oncology Unit, Alessandria Hospital, 15121, Alessandria, Italy.
| |
Collapse
|
10
|
Caorsi R, Grossi A, Insalaco A, Alessio M, Martino S, Cortis E, Morreale A, Caroli F, Martini A, Ceccherini I, Gattorno M. Prevalence of CECR1 mutations in pediatric patients with polyarteritis nodosa, livedo reticularis and/or stroke. Pediatr Rheumatol Online J 2015. [PMCID: PMC4597065 DOI: 10.1186/1546-0096-13-s1-o87] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
11
|
Fusco V, Fasciolo A, Gaino R, Tartara D, De Martino I, Alessio M, Benzi L, Rapetti M, Cammarata R, Caravaggio E, Vincenti M, Gugliemini P. Osteonecrosis of jaw (ONJ) with and without bone exposure in patients receiving antiangiogenic agents (+/- bisphosphonates or denosumab). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv346.15] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Pastore S, Ferrara G, Sandrin C, Breda L, Alessio M, Teruzzi B, Martino S, Gerloni V, Cattalini M, Meini A, La Torre F, Lepore L, Taddio A. AB1019 Chronic Nonbacterial Osteomyelitis in a Pediatric Population: A Multicenter Observational Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
13
|
Caorsi R, Grossi A, Insalaco A, Alessio M, Martino S, Cortis E, Morreale A, Caroli F, Martini A, Ceccherini I, Gattorno M. SAT0484 Prevalence of Cecr1 Mutations in Pediatric Patients with Polyarteritis Nodosa, Livedo Reticularis and/or Stroke. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
14
|
Fontana F, Timpone L, Aloy G, Orlando F, Alessio M. AB0995 Protein Losing Enteropathy (PLE) in a Child: The First Clinical Presentation of Systemic Lupus Erythematosus-Like Syndrome? Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
15
|
Timpone L, Forni C, Fontana F, Orlando F, Brin C, Alessio M. FRI0524 Juvenile Dermatomyositis (DM) with Normal Creatine Kinase. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
16
|
Ravera M, Gabano E, Zanellato I, Bonarrigo I, Alessio M, Arnesano F, Galliani A, Natile G, Osella D. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs. J Inorg Biochem 2015; 150:1-8. [PMID: 26042542 DOI: 10.1016/j.jinorgbio.2015.05.012] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2015] [Revised: 05/19/2015] [Accepted: 05/21/2015] [Indexed: 01/25/2023]
Abstract
A series of Pt(IV) anticancer prodrug candidates, having the equatorial arrangement of cisplatin and bearing two aliphatic carboxylato axial ligands, has been investigated to prove the relationship between lipophilicity, cellular accumulation, DNA platination and antiproliferative activity on the cisplatin-sensitive A2780 ovarian cancer cell line. Unlike cisplatin, no facilitated influx/efflux mechanism appears to operate in the case of the Pt(IV) complexes under investigation, thus indicating that they enter by passive diffusion. While Pt(IV) complexes having lipophilicity comparable to that of cisplatin (negative values of log Po/w) exhibit a cellular accumulation similar to that of cisplatin, the most lipophilic complexes of the series show much higher cellular accumulation (stemming from enhanced passive diffusion), accompanied by greater DNA platination and cell growth inhibition. Even if the Pt(IV) complexes are removed from the culture medium in the recovery process, the level of DNA platination remains very high and persistent in time, indicating efficient storing of the complexes and poor detoxification efficiency.
Collapse
Affiliation(s)
- Mauro Ravera
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy
| | - Elisabetta Gabano
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy
| | - Ilaria Zanellato
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy
| | - Ilaria Bonarrigo
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy
| | - Manuela Alessio
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy
| | - Fabio Arnesano
- Dipartimento di Chimica, Università di Bari "Aldo Moro", Via E. Orabona, 4, 70125 Bari, Italy
| | - Angela Galliani
- Dipartimento di Chimica, Università di Bari "Aldo Moro", Via E. Orabona, 4, 70125 Bari, Italy
| | - Giovanni Natile
- Dipartimento di Chimica, Università di Bari "Aldo Moro", Via E. Orabona, 4, 70125 Bari, Italy
| | - Domenico Osella
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy.
| |
Collapse
|
17
|
Bellini G, Olivieri AN, Grandone A, Alessio M, Gicchino MF, Nobili B, Perrone L, Maione S, Miraglia del Giudice E, Rossi F. Association between cannabinoid receptor type 2 Q63R variant and oligo/polyarticular juvenile idiopathic arthritis. Scand J Rheumatol 2015; 44:284-7. [DOI: 10.3109/03009742.2015.1020863] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
18
|
Alessio M, Roggero S, Bussolino F, Saitta M, Malavasi F. Characterization of the murine monoclonal antibody NL07 specific for the human thrombospondin receptor (CD36 molecule). Curr Stud Hematol Blood Transfus 2015:182-6. [PMID: 1720081 DOI: 10.1159/000419359] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- M Alessio
- Dipartimento Genetica, Biologia e Chimica Medica, Università di Torino, Italy
| | | | | | | | | |
Collapse
|
19
|
Federici S, Dolezalova P, Cantarini L, Papadopoulou-Alataki E, Alessio M, Herlin T, Gueli I, Modesto C, Fabio G, Maggio MC, Elorduy MJR, Garibotto F, Insalaco A, Kozlova A, Anton J, Brik R, Frenkel J, Hoppenreijs E, Sormani MP, Martini A, Gattorno M. Perspective validation of the eurofever classification criteria for monogenic periodic fevers. Pediatr Rheumatol Online J 2014. [PMCID: PMC4184335 DOI: 10.1186/1546-0096-12-s1-p82] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
20
|
Zanellato I, Bonarrigo I, Colangelo D, Gabano E, Ravera M, Alessio M, Osella D. Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be? J Inorg Biochem 2014; 140:219-27. [PMID: 25171667 DOI: 10.1016/j.jinorgbio.2014.07.018] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2014] [Revised: 07/29/2014] [Accepted: 07/29/2014] [Indexed: 01/20/2023]
Abstract
The biological properties of a series of cisplatin-based Pt(IV) prodrug candidates, namely trans,cis,cis-[Pt(carboxylato)2Cl2(NH3)2], where carboxylato=CH3(CH2)nCOO(-) [(1), n=0; (2), n=2; (3), n=4; (4), n=6] having a large interval of lipophilicity are discussed. The stability of the complexes was tested in different pH conditions (i.e. from 1.0 to 9.0) to simulate the hypothetical conditions for an oral route of administration, showing a high stability (>90%). The transformation into their active Pt(II) metabolites was demonstrated in the presence of ascorbic acid, with a pseudo-first order kinetics, the half-time of which smoothly decreases as the chain length of carboxylic acid increases. Their antiproliferative activity has been evaluated in vitro on a large panel of human cancer cell lines. As expected, the potency increases with the chain length: 3 and 4 resulted by far more active than cisplatin on all cell lines of about one or two orders of magnitude, respectively. Both complexes retained their activity also on cisplatin-resistant cell line, and exhibited a progressive increase of the selectivity compared with non-tumor cells. These results were confirmed with more prolonged treatment (up to 14days) studied on multicellular tumor spheroids (MCTSs). In this case the Pt(IV) complexes exert a protracted antiproliferative action, even if the drug is removed from the culture medium. Finally, in a time-course experiment of the total platinum evaluation in mice blood (after a single oral administration of the title complexes), 2 gave the best results, representing a good compromise between lipophilicity and water solubility, that increase and decrease respectively on passing from 1 to 4.
Collapse
Affiliation(s)
- Ilaria Zanellato
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale "Amedeo Avogadro", Viale Michel 11, 15121 Alessandria, Italy
| | - Ilaria Bonarrigo
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale "Amedeo Avogadro", Viale Michel 11, 15121 Alessandria, Italy
| | - Donato Colangelo
- Dipartimento di Scienze della Salute, Università del Piemonte Orientale "Amedeo Avogadro", Via Solaroli 17, 28100 Novara, Italy
| | - Elisabetta Gabano
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale "Amedeo Avogadro", Viale Michel 11, 15121 Alessandria, Italy
| | - Mauro Ravera
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale "Amedeo Avogadro", Viale Michel 11, 15121 Alessandria, Italy
| | - Manuela Alessio
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale "Amedeo Avogadro", Viale Michel 11, 15121 Alessandria, Italy
| | - Domenico Osella
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale "Amedeo Avogadro", Viale Michel 11, 15121 Alessandria, Italy.
| |
Collapse
|
21
|
Ruperto N, Brunner H, Constantin T, Wulffraat N, Horneff G, Anton J, Berner R, Corona F, Cuttica R, Desjonqueres M, Fischbach M, Alessio M, Chieng A, Emminger W, Haddad E, Lheritier K, Abrams K, Hruska J, Kim D, Martini A, Lovell D. OP0136 Baseline Characteristics of Patients with Active Systemic JIA Successfully Discontinuing Corticosteroid while Receiving Canakinumab: Secondary Analysis from a Pivotal Phase 3 Trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.341] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
22
|
Naselli A, Cantarini L, Insalaco A, Alessio M, Tommasini A, Gallizzi R, Signa S, Lucherini OM, Caroli F, Ceccherini I, Martini A, Gattorno M. PReS-FINAL-2196: The clinical significance of the Q703K mutation of NLRP3 gene. A multicentric national study. Pediatr Rheumatol Online J 2013. [PMCID: PMC4044456 DOI: 10.1186/1546-0096-11-s2-p186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
23
|
Finetti M, Insalaco A, Cantarini L, D'Alessandro M, Meini A, Breda L, Alessio M, Picco P, Martini A, Gattorno M. PReS-FINAL-2333: Long term efficacy of interleukin-1 receptor antagonist (anakinra) in a multicentric cohort of patients affected by idiopathic recurrent pericarditis. Pediatr Rheumatol Online J 2013. [PMCID: PMC4044188 DOI: 10.1186/1546-0096-11-s2-p323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
24
|
Alessio M, Fontana F, Officioso A, Cotini S, Fontana F, Forni C, Alessio M. PReS-FINAL-2006: Resilience and coping in adolentes with rheumatic illness. Pediatr Rheumatol Online J 2013. [PMCID: PMC4044019 DOI: 10.1186/1546-0096-11-s2-p19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
25
|
Alessio M, Zanellato I, Bonarrigo I, Gabano E, Ravera M, Osella D. Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells. J Inorg Biochem 2013; 129:52-7. [DOI: 10.1016/j.jinorgbio.2013.09.003] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2013] [Revised: 07/25/2013] [Accepted: 09/03/2013] [Indexed: 10/26/2022]
|
26
|
Caorsi R, Insalaco A, Obici L, Cantarini L, Meini A, Alessio M, Lepore L, Zulian F, Caroli F, Ceccherini I, Martini A, Gattorno M. P02-024 - Clinical impact of V198M mutation in NLRP3 gene. Pediatr Rheumatol Online J 2013. [PMCID: PMC3952123 DOI: 10.1186/1546-0096-11-s1-a131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
27
|
Finetti M, Insalaco A, Cantarini L, D'Alessandro M, Meini A, Breda L, Alessio M, Picco P, Martini A, Gattorno M. PW03-018 – Efficacy of Anakinra in recurrent pericarditis. Pediatr Rheumatol Online J 2013. [PMCID: PMC3952450 DOI: 10.1186/1546-0096-11-s1-a244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
|
28
|
Officioso A, Griso G, Russo G, Storace C, Alessio M. AB1114 Juvenile idiopathic arthritis: Can mother mood be a determinant factor in the child illness management? Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Russo G, Orlando F, Forni C, Battagliese A, Alessio M. AB1148 Diagnosis of malignancies in children with musculoskeletal complaints. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Caorsi R, Lepore L, Zulian F, Alessio M, Stabile A, Finetti M, Bibalo C, Martini A, Gattorno M. AB1191 Within-patient analysis during anakinra and canakinumab treatment in cryopyrin associated periodic syndrome. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Russo G, Forni C, Scotti N, Carlomagno R, Alessio M. AB1149 Biologics in the management of pediatric autoimmune and autoinflammatory diseases: Side effects. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Iannaccone S, Cerami C, Alessio M, Garibotto V, Panzacchi A, Olivieri S, Gelsomino G, Moresco RM, Perani D. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat Disord 2012; 19:47-52. [PMID: 22841687 DOI: 10.1016/j.parkreldis.2012.07.002] [Citation(s) in RCA: 153] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2012] [Revised: 05/01/2012] [Accepted: 07/01/2012] [Indexed: 11/18/2022]
Abstract
BACKGROUND Reactive microgliosis, hallmark of neuroinflammation, may contribute to neuronal degeneration, as shown in several neurodegenerative diseases. We in vivo evaluated microglia activation in early dementia with Lewy bodies, still not reported, and compared with early Parkinson's disease, to assess possible differential pathological patterns. METHODS We measured the [(11)C]-PK11195 binding potentials with Positron Emission Tomography, using a simplified reference tissue model, as marker of microglia activation, and cerebral spinal fluid protein carbonylation levels, as marker of oxidative stress. Six dementia with Lewy bodies and 6 Parkinson's disease patients within a year from the onset, and eleven healthy controls were included. Clinical diagnosis was confirmed at a 4-year follow-up. RESULTS In dementia with Lewy bodies as well as in Parkinson's disease, we found significant (p < 0.001) [(11)C]-PK11195 binding potential increases in the substantia nigra and putamen. Patients with Lewy bodies dementia had extensive additional microglia activation in several associative cortices. This was evident also at a single subject level. Significant increase of Cerebral Spinal Fluid protein carbonylation was shown in both patients' groups. CONCLUSIONS [(11)C]-PK11195 Positron Emission Tomography imaging revealed neuroinflammation in dementia with Lewy bodies and Parkinson's disease, mirroring, even at a single subject level, the common and the different topographical distribution of neuropathological changes, yet in the earliest stages of the disease process. Focusing on those events that characterize parkinsonisms and Parkinson's disease may be the key to further advancing the understanding of pathogenesis and to taking these mechanisms forward as a means of defining targets for neuroprotection.
Collapse
Affiliation(s)
- S Iannaccone
- Neurorehabilitation Unit, Department of Clinical Neurosciences, San Raffaele Scientific Institute and Vita-Salute University, Milan, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Russo G, Carlomagno R, Forni C, De Martino L, Capalbo D, Alessio M. Acute adrenal failure (AAF) as the presenting symptom of primary antiphospholipid syndrome (APS). Pediatr Rheumatol Online J 2011. [PMCID: PMC3194616 DOI: 10.1186/1546-0096-9-s1-p252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
34
|
Miettunen P, Pistorio A, Ravelli A, Oliveira S, Alessio M, Cuttica R, Mihaylova D, Espada G, Pasic S, Cortis E, Ozen S, Porras O, Sztajnbok F, Palmisani E, Martini A, Ruperto N. Therapeutic approaches for the treatment of new onset and flared juvenile systemic lupus erythematosus with active renal disease: an international multicenter PRINTO study. Pediatr Rheumatol Online J 2011. [PMCID: PMC3194622 DOI: 10.1186/1546-0096-9-s1-p258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
35
|
Bibalo C, Paloni G, Lepore L, Gattorno M, Finetti M, Zulian F, Martini G, Alessio M, Cattalin M, Stabile A, Rigante D, Insalaco A, Manna R, Gallizzi R, Obici L, Cantarini L, Martino S, Cionsolini R. National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry. Pediatr Rheumatol Online J 2011. [PMCID: PMC3194446 DOI: 10.1186/1546-0096-9-s1-p1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
36
|
Filocamo G, Malattia C, Foeldvari I, Stanevicha V, Nielsen S, Herlin T, Pruunsild C, Zulian F, Balogh Z, Dressler F, Rumba I, Alpigiani MG, Cortis E, Falcini F, Trauzeddel R, Calcagno G, Lepore L, Alessio M, Glass DN, Thompson SD, Martini A, Ruperto N. JIA affected sibling pairs present high correlation for ANA and ILAR category. Pediatr Rheumatol Online J 2011. [PMCID: PMC3194550 DOI: 10.1186/1546-0096-9-s1-p193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
37
|
Scotti N, Russo G, Carlomagno R, Forni C, Orlando F, Casa MGD, Alessio M. Septic sacroiliitis in children-a diagnostic challenge. Pediatr Rheumatol Online J 2011. [PMCID: PMC3194595 DOI: 10.1186/1546-0096-9-s1-p233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
38
|
Officioso A, Griso G, Storace C, Battagliese A, Carlomagno R, Alessio M. Juvenile idiopathic arthritis (JIA): can an integrated medicine be possible? Pediatr Rheumatol Online J 2011. [PMCID: PMC3194552 DOI: 10.1186/1546-0096-9-s1-p195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
39
|
Caorsi R, Lepore L, Zulian F, Alessio M, Stabile A, Finetti M, Martini A, Gattorno M. Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up. Pediatr Rheumatol Online J 2011. [PMCID: PMC3194580 DOI: 10.1186/1546-0096-9-s1-p22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
40
|
Zanellato I, Bonarrigo I, Sardi M, Alessio M, Gabano E, Ravera M, Osella D. Evaluation of platinum-ethacrynic acid conjugates in the treatment of mesothelioma. ChemMedChem 2011; 6:2287-93. [PMID: 22025407 DOI: 10.1002/cmdc.201100426] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2011] [Revised: 10/11/2011] [Indexed: 01/03/2023]
Abstract
Malignant pleural mesothelioma (MPM) cells are characterized by chemoresistance associated with glutathione (GSH) metabolism. Ethacrynic acid (EA) is able to inhibit the detoxifying enzyme glutathione-S-transferase (GST), which catalyzes the conjugation between GSH and Pt-based drugs. With the aim of obtaining active bifunctional drugs, a Pt(II) complex containing two EA moieties as leaving groups, namely cis-diamminobis(ethacrynato)platinum(II), was synthesized, characterized, and tested on four MPM cell lines. The resulting antiproliferative activity was compared with that elicited by the analogue Pt(IV) complex, cis,cis,trans-diamminodichloridobis(ethacrynato)platinum(IV) (ethacraplatin) and by the co-administration of free EA and cisplatin. The Pt(II) and Pt(IV) bifunctional complexes showed poorer performance than the reference drug cisplatin alone or in combination with EA. After treatment, cellular GST activity remained consistently unchanged, while the GSH level increased.
Collapse
Affiliation(s)
- Ilaria Zanellato
- Dipartimento di Scienze dell'Ambiente e della Vita, Università del Piemonte Orientale Amedeo Avogadro, Viale Michel 11, 15121 Alessandria, Italy
| | | | | | | | | | | | | |
Collapse
|
41
|
Ravera M, Gabano E, Sardi M, Alessio M, Osella D. Electrochemical Biosensor Assay of the Interaction between [PtCln(NH3)4-n](2-n) (n = 0-4) Complexes and ds-DNA. Eur J Inorg Chem 2011. [DOI: 10.1002/ejic.201001338] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
42
|
Alessio M, Indaco R, Carlomagno R, Romano A. Isolated eye-lid ptosis as initial manifestation of pediatric Behcet's Disease (BD). Pediatr Rheumatol Online J 2008. [PMCID: PMC3334077 DOI: 10.1186/1546-0096-6-s1-p269] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
43
|
Filocamo G, Meiorin S, Saad-Magalhães C, Pistorio A, Ravelli A, Cortis E, Mihaylova D, Alessio M, Arguedas O, Garay S, Martini A, Ruperto N. 3.5 Comparison of functional ability in juvenile idiopathic arthritis, juvenile dermatomyositis, juvenile systemic lupus erythematosus and healthy controls. An analysis of the PRINTO database. Pediatr Rheumatol Online J 2008. [PMCID: PMC3334196 DOI: 10.1186/1546-0096-6-s1-s7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
44
|
Paloni G, Gattorno M, Alessio M, Rigante D, Cattalini M, Zulian F, Lepore L. 12.3 Long-term follow up of patients with CINCA syndrome: efficacy and tolerability of Anakinra treatment. Pediatr Rheumatol Online J 2008. [PMCID: PMC3334182 DOI: 10.1186/1546-0096-6-s1-s25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
45
|
Ferrari C, Trail L, Pilkington C, Maillard S, Cuttica R, Katsicas MM, Russo R, Bandeira M, Ferriani V, Oliveira S, Saad-Magalhaes C, Silva CA, Baca V, Burgos-Vargas R, Solis-Vallejo E, Alessio M, Alpigiani MG, Corona F, Falcini F, Gerloni V, Lepore L, Magni-Manzoni S, Zulian F, Ruperto N, Pistorio A, Felici E, Rossi F, Sala E, Martini A, Ravelli A. 8.5 Predictors of long-term outcome of Juvenile Dermatomyositis (JDM): a Multicenter, Multinational Study of 490 patients. Pediatr Rheumatol Online J 2008. [PMCID: PMC3334175 DOI: 10.1186/1546-0096-6-s1-s19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
46
|
Nielsen S, Ruperto N, Gerloni V, Simonini G, Cortis E, Lepore L, Alpigiani MG, Zulian F, Corona F, Alessio M, Barcellona R, Gallizzi R, Rossi F, Magni-Manzoni S, Lombardini G, Filocamo G, Raschetti R, Martini A, Ravelli A. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008; 26:688-692. [PMID: 18799107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
OBJECTIVE To investigate the rate of radiographic progression, as measured with the carpo-metacarpal ratio (Poznanski score), during etanercept (ETN) therapy in children with polyarticular juvenile idiopathic arthritis (JIA). METHODS Patients included in the Italian ETN registry who had a standard radiograph of both hands and wrists in the posteroanterior view made at start of treatment and after 1 year were included in the study. The clinical response was assessed by means of the ACR Pediatric definition of improvement. Radiographic progression was determined by calculating the change in the Poznanski score between the baseline and the 1-year radiographs. RESULTS A total of 40 patients were studied. The frequency of ACR pediatric 30, 50, and 70 response at 1 year was 77%, 72%, and 50%, respectively. The median change in the Poznanski score between baseline and 1 year was + 0.3 units, meaning that, on average, patients experienced improvement in radiographic progression. CONCLUSION Our pilot study provides evidence that ETN is potentially capable of reducing the progression of radiographic joint damage in JIA. This finding deserves confirmation in a controlled trial.
Collapse
Affiliation(s)
- S Nielsen
- Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genova, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Spreafico A, Grigorieva J, Cattaneo A, Belli C, Tsypin M, Roder H, Giovannini M, Alessio M, Gregorc V, Bachi A. Changes in serum proteomic profile of non-small cell lung cancer (NSCLC) patients during therapy with epidermal growth factor receptor tirosine kinase inhibitors (EGFR-TKIs): Preliminary report. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Muzio M, Scielzo C, Frenquelli M, Bachi A, De Palma M, Alessio M, Ghia P, Caligaris-Cappio F. HS1 complexes with cytoskeleton adapters in normal and malignant chronic lymphocytic leukemia B cells. Leukemia 2007; 21:2067-70. [PMID: 17508001 DOI: 10.1038/sj.leu.2404744] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
49
|
Caroli F, Pontillo A, D'Osualdo A, Travan L, Ceccherini I, Crovella S, Alessio M, Stabile A, Gattorno M, Tommasini A, Martini A, Lepore L. Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford) 2006; 46:473-8. [PMID: 16920754 DOI: 10.1093/rheumatology/kel269] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE We report the experience of the Italian Registry of patients affected by chronic infantile neurological, cutaneous, articular (CINCA) syndrome. The clinical and genetic features of 12 unrelated Italian patients with CINCA syndrome are described, focusing on the possible influence of the presence of CIAS1/cryopyrin mutations on the phenotype of the disease and on its prognosis. METHODS The clinical features of 12 Italian CINCA patients were evaluated. Genomic DNA of the patients was sequenced using specific primers for CIAS1 and ASC genes. RESULTS Our patients shared typical CINCA characteristics and, sometimes, remarkable perinatal events, peculiar of CIAS1-mutated patients. Seven patients carried CIAS1 missense mutation, localized within the nucleotide binding domain of cryopyrin. Four previously described mutations and three new heterozygous CIAS1 missense mutations were identified. ASC gene, encoding for a direct interactor of cryopyrin, was not mutated in Italian CINCA patients. Finally, we reported the efficacy and safety of anti-IL1 therapy (Anakinra) in seven patients with a particularly severe CINCA phenotype. CONCLUSION Despite some common signs-used as syndrome hallmarks-we observed a high variability in symptoms, genetic results and outcomes in Italian CINCA patients. In contrast with other authors, we cannot find out any correlation between mutations in CIAS1 and CINCA severity, but we underlined the concomitance of perinatal events and mental retardation only in CIAS1 mutated subjects. Finally, we confirmed the efficacy of Anakinra treatment, both in CIAS1-mutated and non-mutated patients.
Collapse
Affiliation(s)
- F Caroli
- Department of Molecular Genetics, IRCCS G. Gaslini, Genoa, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Scielzo C, Camporeale A, Geuna M, Alessio M, Poggi A, Zocchi MR, Chilosi M, Caligaris-Cappio F, Ghia P. ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia 2006; 20:689-95. [PMID: 16482211 DOI: 10.1038/sj.leu.2404138] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
ZAP-70 tyrosine kinase is involved in signalling pathways following T-cell receptor stimulation and was originally described only in T cells and natural killer cells. ZAP-70 expression has been reported in normal mouse B lineage cells and in human malignant B lymphocytes, mainly in chronic lymphocytic leukemia (CLL) where it correlates with clinical outcome. We analyzed several B-cell lines and ex vivo malignant B cells, ranging from acute lymphoblastic leukemia to multiple myeloma and reflecting different stages of B-cell differentiation, and they showed ZAP-70 expression regardless their maturation stage. We then analyzed by Western blot and flow cytometry different human normal B-lymphocyte subpopulations: naïve, germinal center and memory B cells from tonsils, CD19+ CD5+ cells from cord blood and CD19+ lymphocytes from peripheral blood. All expressed ZAP-70 protein, though at different levels depending on their differentiation, activation and tissue localization. In addition, ZAP-70 expression levels could be modulated following stimulation via the B-cell receptor. These findings implicate a potential role of ZAP-70 in the signalling pathway of B lymphocytes at different maturational stages, indicate that ZAP-70 expression is not a CLL-specific feature among B-cell malignancies and suggest that the absence of ZAP-70 rather than its presence should be considered abnormal for malignant B lymphocytes.
Collapse
Affiliation(s)
- C Scielzo
- Department of Oncology, Università Vita Salute - San Raffaele, Milan, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|